Whitehawk CSO awarded 282,340 stock options

Whitehawk Therapeutics, Inc. granted Chief Scientific Officer David Dornan a stock option to acquire 282,340 shares of common stock at an exercise price of $3.54 per share, expiring on April 1, 2036.

Accepted by SEC EDGAR 04/03/2026 - 06:22 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. granted Chief Scientific Officer David Dornan a stock option to acquire 282,340 shares of common stock at an exercise price of $3.54 per share, expiring on April 1, 2036.

According to the vesting terms, if he continues as a service provider, 25% of the option will vest on the one-year anniversary of the Vesting Commencement Date of April 1, 2026, with the remaining shares vesting in equal monthly installments over the following three years.

Insider Trade Summary

Grant/Award: 282,340 shares

Grant/Award 1 txn

Insider Dornan David

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	282,340	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 282,340 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026.

Key Figures

Option grant size: 282,340 shares Exercise price: $3.54 per share Expiration date: April 1, 2036 +2 more

5 metrics

Option grant size 282,340 shares Stock Option (right to buy) granted to CSO

Exercise price $3.54 per share Conversion/exercise price of stock option

Expiration date April 1, 2036 Option term end date

Initial vesting portion 25% of shares Vests one year after April 1, 2026

Monthly vesting cadence 1/48 of shares Vests monthly after first anniversary until year four

Key Terms

Stock Option (right to buy), Vesting Commencement Date, Equity Incentive Plan

3 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Vesting Commencement Date financial

""Vesting Commencement Date" shall mean April 1, 2026."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Equity Incentive Plan financial

"as defined in the Issuer's 2021 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Whitehawk Therapeutics (WHWK) report for David Dornan?

Whitehawk Therapeutics reported a grant of stock options to Chief Scientific Officer David Dornan. He received options for 282,340 shares of common stock at a $3.54 exercise price, forming part of his equity-based compensation package under the company’s 2021 Equity Incentive Plan.

How many Whitehawk Therapeutics (WHWK) shares are covered by the new option grant?

The new option grant covers 282,340 shares of Whitehawk Therapeutics common stock. These shares are not issued immediately; they become exercisable only as the option vests over time, subject to Dornan’s continued service with the company under the stated vesting schedule.

What is the exercise price of David Dornan’s Whitehawk Therapeutics (WHWK) stock options?

The exercise price for David Dornan’s stock options is $3.54 per share. This means he can buy Whitehawk Therapeutics common stock at $3.54 once options vest and are exercised, regardless of the market price at that future time, subject to plan and option terms.

When do David Dornan’s Whitehawk Therapeutics (WHWK) options start vesting?

The options use a Vesting Commencement Date of April 1, 2026. Twenty-five percent of the shares vest on the one-year anniversary of that date, with the remaining 75% vesting in equal monthly installments over the following three years, contingent on continued service.

What is the expiration date of the Whitehawk Therapeutics (WHWK) options granted to Dornan?

The stock options granted to David Dornan expire on April 1, 2036. If unexercised by that date, the right to buy Whitehawk Therapeutics common shares under this grant will lapse, following the standard long-dated option structure typical for executive equity incentives.

Is the Whitehawk Therapeutics (WHWK) option grant to Dornan an open-market purchase or sale?

The transaction is an option grant classified as an acquisition, not an open-market trade. Dornan received the options as compensation, at no purchase price today, and may later choose to exercise them at $3.54 per share if they vest and conditions are satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dornan David

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.54	04/01/2026		A		282,340		(1)	04/01/2036	Common Stock	282,340	$0	282,340	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026.

	/s/ Stephen Rodin, as Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)